Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Origo Acquisition Corp | s102268_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 25, 2015
CB PHARMA ACQUISITION CORP.
(Exact Name of Registrant as Specified in Charter)
| Cayman Islands | 001-36757 | N/A |
| (State or Other
Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
3 Columbus Circle
15th Floor
New York, NY 10019
(Address of Principal Executive Offices) (Zip Code)
(781) 652-4500
(Registrant’s Telephone Number, Including Area Code)
24 New England Executive Park, Suite 105, Burlington, MA 01803
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☒ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Item 8.01 Other Events
On November 25, 2015, CB Pharma Acquisition Corp. (the “Company”) issued a press release related to a non-binding offer to acquire National Holdings Corporation. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits:
| Exhibit | Description |
| 99.1 | Press Release |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 25, 2015
CB PHARMA ACQUISITION CORP.
| By: | /s/ Lindsay A. Rosenwald |
Name: Lindsay A. Rosenwald
| Title: | Chief Executive Officer |